Nanomedicine News

RSS

Alnylam Reports Positive Phase I Clinical Study Results for Lipid Nanoparticle-Based ALN-PCS

According to Tekmira Pharmaceuticals, a specialist in RNA interference (RNAi) therapeutics, Alnylam Pharmaceuticals has reported positive results on its Phase I clinical study of ALN-PCS, a target-specific RNAi therapeutic for PCSK9 called ALN-PCS that uses Tekmira Pharmaceuticals’ lipid nanoparticle technology to treat severe hypercholesterolemia.

23 Apr 2012

New Nanochain Targeted Delivery System for Effective Cancer Treatment

A research team led by Efstathios Karathanasis from the Case Western Reserve University has developed a novel nanochain targeted delivery system that delivers an anti-cancer medicine into hard-to-reach areas of tumor.

20 Apr 2012

Study Reveals Smaller Nanomedicines are Ideal for Cancer Treatment

Researchers from the Massachusetts General Hospital have discovered that tumor blood vessel normalization by antiangiogenesis drugs only improves the delivery of smaller nanotherapy molecules, but blocks the supply of larger nanomedicine molecules to cancer cells.

12 Apr 2012

Nanobubble Injection Mechanism Offers New Approach for Drug and Gene Delivery

Scientists from Rice University have teamed up with the Baylor College of Medicine (BCM) and the University of Texas MD Anderson Cancer Center to study drug and gene delivery. In experimental studies, which involved drug-resistant cancer cells, the scientists discovered that when compared to conventional drug treatment, chemotherapy drugs loaded with nanobubbles were 30x more lethal to cancer cells and needed just 1/10th of the clinical dose.

11 Apr 2012

MIT Researchers Develop Protein-Factory Nanoparticles for Cancer Treatment

A research team from Massachusetts Institute of Technology (MIT) has designed a new kind of nanoparticle that is capable of producing proteins on demand.

From Massachusetts Institute of Technology 10 Apr 2012

Drug-Loaded Gold Nanostars Hitchhike into Cancer Cell Nucleus

Scientists at Northwestern University have developed gold nanostars for effective delivery of drugs into a cancer cell's nucleus. The study was performed on human ovarian and cervical cancer cells.

7 Apr 2012

Phase I Clinical Study of Targeted Therapeutic Nanoparticles Shows Positive Results

Ongoing Phase I clinical trials of targeted therapeutic nanoparticles developed for delivering docetaxel, an anti-cancer drug for treating breast, prostate, lung and other cancers, have demonstrated positive results.

6 Apr 2012

BIND Biosciences Reports Positive Phase I Clinical Results on First Prostate Nanomedicine

A nanomedicine research project at the David H. Koch Institute for Integrative Cancer Research at Massachusetts Institute of Technology (MIT) has delivered a first-of-its-kind nanomedicine capable of targeting prostate cancer cells and delivering high concentrations of docetaxel chemotherapy in Phase I clinical studies.

6 Apr 2012

LATITUDE Pharmaceuticals Creates Injectable Liquid Glucagon Formulation, Nano-G

Researchers at LATITUDE Pharmaceuticals have created a first-of-its-kind stable, injectable liquid glucagon formulation called Nano-G, which is based on the company’s injectable nanoemulsion drug delivery platform called Nano-E.

5 Apr 2012

Researchers Demonstrate Cargo-Carrying Bacteria to Deliver Nano-Medicine

At the American Chemical Society’s 243rd National Meeting & Exposition a research team led by David H. Gracias from the Johns Hopkins University has reported about a research on ‘backpacking’ bacteria that can serve as a carrier to deliver nano-medicine across the body.

From American Chemical Society 31 Mar 2012